Non-small cell lung, colorectal, pancreatic, and head & neck cancers rank among the deadliest cancers in the U.S., combining to kill over 200,000 each year. High levels of COX-2 enzymatic activity are a strong prognostic marker of poor overall survival in these cancers. COX-2 activity can also become elevated as resistance develops to current standard-of-care therapies, such as epidermal growth factor receptor (EGFR) inhibitors and some chemotherapeutics. At the same time, clinical studies have shown that elevated COX-2 activity and COX-2 derived prostaglandins can serve as biomarkers to select those likely to respond to coxib therapy with dramatic benefit.
Euclises’ clinical development strategy calls for utilizing a non-invasive prostaglandin biomarker to demonstrate early pharmacodynamic response to treatment and to select and enroll patients in Phase 2/3 studies.